Kaken Pharma Q1 FY26 profit attributable to owners swings to ¥8.44 billion; net sales rise 59.8% to ¥30.15 billion

Reuters2026/08/07 06:41

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Kaken Pharmaceutical posted Q1 net sales of JPY 30.15 billion, up 59.8% year-on-year.
Operating profit returned to profit at JPY 10.9 billion; ordinary profit returned to profit at JPY 11.26 billion.
Profit attributable to owners of the parent swung to JPY 8.44 billion; basic EPS was JPY 222.86.
For the year ending March 31, 2027, it reaffirmed forecasts for net sales of JPY 89.9 billion and profit attributable to owners of the parent of JPY 6.5 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kaken Pharmaceutical Co. Ltd. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Kaken Pharma Q1 FY26 profit attributable to owners swings to ¥8.44 billion; net sales rise 59.8% to ¥30.15 billion

You may also like

Crypto prices